HL7 FHIR® Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment)

This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.1.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions

OncotypeDxDCISRiskScoreInterpretationCS


<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="oncology-OncotypeDxDCISRiskScoreInterpretationCS"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
<p><b>BC OncotypeDxDCISRiskScoreInterpretationCS CodeSystem</b></p>
<p>Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score</p>
</div>
  </text>
  <url
       value="http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS"/>
  <identifier>
    <system value="http://hl7.org/fhir/us/breastcancer"/>
    <value value="oncology.OncotypeDxDCISRiskScoreInterpretationCS"/>
  </identifier>
  <version value="0.1.0"/>
  <name value="OncotypeDxDCISRiskScoreInterpretationCS"/>
  <title value="BC OncotypeDxDCISRiskScoreInterpretationCS CodeSystem"/>
  <status value="draft"/>
  <date value="2018-04-01T00:00:00+11:00"/>
  <publisher
             value="The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://standardhealthrecord.org"/>
    </telecom>
  </contact>
  <description
               value="Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score"/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="3"/>
  <concept>
    <code value="low_risk"/>
    <display
             value="Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."/>
    <definition
                value="Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."/>
  </concept>
  <concept>
    <code value="intermediate_risk"/>
    <display
             value="Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects."/>
    <definition
                value="Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects."/>
  </concept>
  <concept>
    <code value="high_risk"/>
    <display
             value="Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."/>
    <definition
                value="Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."/>
  </concept>
</CodeSystem>